All In Biotech

Drug Trial Radar · NCT04535531

A Phase 3 Molluscum Contagiosum Efficacy and Safety Study

A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy and Safety of SB206 and Vehicle Gel Once Daily in the Treatment of Molluscum Contagiosum

Last checked: Nov 19, 2026Latest source record: Jan 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 891 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

891

Actual

Start

Sep 1, 2020

Primary completion

Apr 28, 2021

Study completion Jul 28, 2021

Sponsor

Lead sponsor
Novan, Inc.Industry
Sponsor type
Industry
Collaborators
Therapeutics, Inc.; Synteract, Inc.
First posted
Sep 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 850 subjects 6 months of age and older with molluscum contagiosum (MC). Subjects or their caregivers will apply SB206 10.3% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at Baseline and new treatable lesions that arise during the course of the study.

Conditions

  • Molluscum Contagiosum

Interventions

  • SB206 10.3% berdazimerDrug

    Topically once daily

  • vehicle gelDrug

    Topically once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Clearance of All Treatable MC at Week 12Time frame: 12 Weeks

Locations

55 sites in 1 country. Site status is shown where the registry gives one.

  • Site #312

    Glendale, Arizona

  • Site #101

    Hot Springs, Arkansas

  • Site #272

    Rogers, Arkansas

  • Site #336

    Fountain Valley, California

  • Site #329

    Fremont, California

  • Site# 348

    Fresno, California

  • Site #161

    San Diego, California

  • Site #327

    Thousand Oaks, California

  • Site #325

    Greenwood Village, Colorado

  • Site #335

    Apopka, Florida

  • Site #342

    Boca Raton, Florida

  • Site #333

    Fort Lauderdale, Florida

  • Site #334

    Homestead, Florida

  • Site #278

    Miami, Florida

  • Site #314

    Miami Lakes, Florida

  • Site #341

    Orlando, Florida

  • Site #227

    Sanford, Florida

  • Site #305

    Tampa, Florida

  • Site #116

    Newnan, Georgia

  • Site #340

    Chicago, Illinois

  • Site #253

    Rolling Meadows, Illinois

  • Site #288

    Evansville, Indiana

  • Site #310

    Plainfield, Indiana

  • Site #328

    Bowling Green, Kentucky

  • Site #347

    Lexington, Kentucky

  • Site # 117

    Louisville, Kentucky

  • Site #294

    Owensboro, Kentucky

  • Site #321

    Baton Rouge, Louisiana

  • Site# 349

    Covington, Louisiana

  • Site #332

    New Orleans, Louisiana

  • Site #297

    New Orleans, Louisiana

  • Site #330

    Rockville, Maryland

  • Site #346

    Brighton, Massachusetts

  • Site #274

    Clarkston, Michigan

  • Site #121

    New Brighton, Minnesota

  • Site #338

    Omaha, Nebraska

  • Site #201

    Berlin, New Jersey

  • Site #331

    Verona, New Jersey

  • Site #279

    Greensboro, North Carolina

  • Site #250

    Portland, Oregon

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.